The Drug and Therapeutics Bulletin (DTB) features a review of cognitive behavioural therapy (CBT) for schizophrenia. The authors found that as an adjunct to routine care, evidence suggests CBT is more effective than routine care alone, both for positive and negative symptoms; and it also appears to be a potentially cost-effective intervention. However, some patients may be too agitated, paranoid or thought disordered to receive such therapy. The authors note that though CBT is available on the NHS, there are limited numbers of trained practitioners at present, which could limit implementation of recommendations from NICE that all patients with a diagnosis of schizophrenia should be offered CBT.